Clinical Trial Update: A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures [Phase 1]

View source ↗

Summary

Completed Phase 1 study assessing pharmacokinetics, safety and tolerability of topiramate in infants aged 1-24 months with refractory partial-onset seizures.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Topamax (Topiramate)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Seizures | Phase 1 | Status: COMPLETED